Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
The study remains ongoing to assess the additional key secondary endpoint of overall survival.
- The study remains ongoing to assess the additional key secondary endpoint of overall survival.
- Results of the confirmatory trial showed that KRAZATI demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to standard-of-care chemotherapy as a second-line or later treatment for these patients.
- KRAZATI had no new safety signals and the safety data was consistent with the known safety profile.
- Zai Lab thanks the patients and investigators involved in the KRYSTAL-12 clinical trial.